Site na Nzukọ Kwa Afọ nke 32 nke Urology Association (CUA) nke a na-aga ime na Dalian, m na-amalite ọzọ, na-atụgharịghachi ihe ọmụma m gara aga banyere endoscopy urological. N'ime afọ m niile nke endoscopy, ahụtụbeghị m otu ngalaba na-enye ụdị endoscopes dịgasị iche iche, gụnyere ngwa anya, eletrọnịkị, na nkọwa dị iche iche. Ọzọkwa, endoscopes urological na-agbanwe ngwa ngwa, na n'ime ụlọ, a na-enye ha aha ndị siri ike dị ka "cannonscope" na "okirikiri ụgbọelu." Ahụmahụ mbụ m mere na ha dị ịtụnanya. M na mbụ chịkọtara ndepụta nke ọdịdị na ụdị nke mgbanwe na isiike endoscopes, nke na-eje ozi dị ka a bara uru mmụta ahụmahụ maka ọrụ m.
N'oge na-adịbeghị anya, a na m amụ endoscopy urological na echiche efu. M ga-edekọ ya dịka ebe ọrịa si dị. Tupu ịmụta, m ga-ebu ụzọ ghọta ụfọdụ isi data.
Data na ọnụ ọgụgụ nke ịwa ahụ chọrọ maka ụfọdụ ọnọdụ urological
E kewara Urology ugbu a n'ime akụkụ urinary elu (akụrụ na ureter), traktị urinary ala (bladder na prostate), na andrology. Ọzọkwa, na ọnụ ọgụgụ mmadụ merela agadi, a na-atụ anya na ọrịa urological ga-abawanye. Isi mmalite data: Nnyocha e bipụtara na Akụkọ Sayensị sitere na Urology Team of the First Affiliated Hospital of Soochow University mere nyocha nke mbụ gbasara ibu zuru ụwa ọnụ nke BPH (benign prostate hyperplasia) site na 1990 ruo 2021 dabere na nchekwa data GBD 2021. Nnyocha nke ire ere gosipụtara na 61% nke mmụba zuru ụwa ọnụ na ikpe bụ n'ihi ịka nká nke ọnụ ọgụgụ mmadụ, 29% na mmụba ọnụ ọgụgụ mmadụ, yana 10% maka mgbanwe ọrịa ọrịa.
N'ọgwụgwụ nke 2024, ndị China ndị gbara afọ 60 na karịa eruola nde 310.31 (ihe dị ka nde 310), na-aza 22.0% nke ọnụ ọgụgụ mmadụ niile; n'ime ha, ndị bi na 65 na karịa bụ 220.23 nde (ihe dị ka nde 220), na-aza 15.6% nke ngụkọta ndị bi.
Ọrịa cancer prostate (CA): A họọrọ nke mbụ n'etiti ọrịa cancer urinary tract, yana ọnụọgụ ọnụọgụ nke 13.42 n'ime mmadụ 100,000. Dabere na obodo nwere nde mmadụ 5, enwere ikpe ọhụrụ 671 kwa afọ. Dabere na nyocha 2025 “Prostate Cancer Epidemiological Trends, Genomic Characteristics, and Future Direction for Optimized Management in China,” ihe dị ka 54% nke ndị ọrịa nọ na mba m nwere metastases dị anya na nyocha mbụ. Ya mere, ọnụ ọgụgụ ndị ọrịa nwere ihe ngosi ịwa ahụ bụ ihe dịka 671 * 0.46 = 308.
Ọrịa afọ ọsịsa: Ọnụego nrịanrịa bụ 9.29 n'ime mmadụ 100,000, yana ọnụ ọgụgụ ikpe ọhụrụ kwa afọ dị ihe dị ka 465 n'obodo nwere nde mmadụ ise. Dabere na data dị n'ịntanetị, na-eche na 75% NMIBC (Tis, Ta, T1), ọnụ ọgụgụ kwa afọ nke ọhụụ ọhụrụ nwere ihe ngosi ịwa ahụ bụ 348. Laparoscopic renal cancer: Ọnụego ya bụ 7.37 kwa mmadụ 100,000, yana ọnụ ọgụgụ ọhụrụ kwa afọ nke ihe dịka 368 n'ime obodo nwere nde mmadụ 5. Dabere na njirimara pathological nke "Ọmụmụ Ihe Ọmụmụ nke afọ iri na mmekọrịta dị n'etiti usoro ịwa ahụ na Clinicopathological Characteristics of Renal Cell Carcinoma" nke Peking University First Hospital bipụtara, ọkwa pT1 na-egosi 79.6%, na-ebute ihe ngosi ịwa ahụ a na-eme atụmatụ na ihe dị ka 293. Laparoscopic benign on above hyperplasia prostatic data: hyperplasia prostatic data. 2024, a ga-enwe nde mmadụ 310.31 na obodo m ndị gbara afọ 60 na karịa, na-aza 22.03% nke ndị bi na ya, nke ihe dịka 48.73% bụ nwoke (bịa, ụmụ nwoke, ị naghị ebi ogologo oge dịka ụmụ nwanyị). Mmetụta nke BPH na ndị agadi 60 na karịa bụ 50%, nke 10% chọrọ ịwa ahụ. Ọnụ ọgụgụ ndị chọrọ ọgwụgwọ BPH n'obodo nwere nde mmadụ 5 bụ: nde 5 * 22.03% * 48.73% * 50% * 10% ≈ 26,838 ndị mmadụ, nke bụ ọtụtụ ihe.
Nkume urinary: Enweghị data gọọmentị dị. Dabere na ọnụ ọgụgụ ihe omume 5%, 25% chọrọ ọgwụgwọ ịwa ahụ. N'obodo nwere nde mmadụ ise, ihe omume na ọgwụgwọ kwa afọ bụ ihe dịka 62,500, nke karịrị akarị. N'ezie, nke a bụ oke oke. A na-eji lithotripsy extracorporeal, ureteroscopic laser lithotripsy, na nephrolithotomy percutaneous nwere pneumatic (laser) lithotripsy.
Site n'elu ruo ala site na ọnọdụ anatomical
nephrolithotomy nke anụ ahụ
Percutaneous nephrolithotomy (PCNL) bụ usoro mkpasu iwe nke na-emepụta ọwa site na akpụkpọ ahụ iji gwọọ nkume akụrụ ma ọ bụ ọnya. A na-ejikarị ya agwọ nnukwu (> 2 cm) ma ọ bụ nkume akụrụ dị mgbagwoju anya. Ihe ndị bụ isi uru ya dị na obere mmerụ ahụ, mgbake ngwa ngwa, na ọnụ ọgụgụ dị elu nke ikpochapụ nkume. Nephroscopes na-adịwanye ntakịrị na dayameta, yana ọwa ọkọlọtọ (24-30 Fr), microchannels (16-22 Fr), na ọwa ultrafine (<16 Fr). Ngwa lithotripsy yiri agịga nwere dayameta gburugburu 1.4 mm dịkwa ugbu a. Percutaneous nephrolithotomy bụ akụrụngwa ọkọlọtọ na ụlọ ọrụ lithotripsy urological.
Nephroscope percutaneous nwere oghere nlele nke 12°, n'ọbọ elliptical, dayameta mpụta nke 8.5 Fr/12 Fr, ogologo ọrụ dị irè nke ihe dịka 250 mm, yana ọwa na-arụ ọrụ nke ihe dịka 6 Fr.
Anyị, Jiangxi Zhuoruihua Medical Instrument Co., Ltd., bụ a emeputa na China ọkachamara na endoscopic consumables, na-agụnye GI akara dị ka biopsy forceps, hemoclip, polyp ọnyà, sclerotherapy agịga, ịgba catheter, cytology brushes, guidewire, nkume eweghachite nkume, nasal biliary nkata, nasal biliary nkata na ọtụtụ ebe. ERCP. Na usoro Urology, dị kauretral ohere n'ọbọ na mmirinaureteral ohere n'ọbọ,Nkata mweghachi nke Urinary Nkume mkpofu, nausoro nke urologywdg.
Ngwaahịa anyị bụ CE asambodo, na osisi anyị bụ ISO asambodo. Ebupụla ngwongwo anyị na Europe, North America, Middle East na akụkụ nke Eshia, na-enwetakwa ndị ahịa nke nnabata na otuto!
Oge nzipu: Sep-22-2025